CLINICAL TRIAL: ADENOVIRUS CD-154 IN SUBJECTS WITH CLL

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Primary Objectives Determine and monitor the biological responses in patients with Non-Hodgkin lymphoma (NHL) restricted to follicular lymphoma, diffuse large cell lymphoma, mantle cell lymphoma and small lymphocytic lymphoma/Chronic lymphocytic leukemia (SLL/CLL) treated with repeat intranodal injections of Ad-ISF35. Secondary Objectives 1) Determine the safety of repeat administration of Adenovirus-CD154 (Ad-ISF35) injected directly into lymph nodes of patients with Non-Hodgkin lymphoma (NHL) including follicular lymphoma, diffuse large cell lymphoma, mantle cell lymphoma and small lymphocytic lymphoma/Chronic lymphocytic leukemia (SLL/CLL). 2) Determine pharmacodynamic (PD) parameters in patients treated with repeat intranodal injections of Ad-ISF35.